Found: 6
Select item for more details and to access through your institution.
Adding candesartan-HCTZ to rosuvastatin increased adverse events but not benefits in patients at intermediate CV risk.
- Published in:
- ACP Journal Club, 2016, v. 165, n. 2, p. 7, doi. 10.7326/ACPJC-2016-165-2-008
- By:
- Publication type:
- Article
Combination candesartan-HCTZ did not reduce major CV events in patients at intermediate CV risk.
- Published in:
- ACP Journal Club, 2016, v. 165, n. 2, p. 6, doi. 10.7326/ACPJC-2016-165-2-007
- By:
- Publication type:
- Article
Rosuvastatin reduced major cardiovascular events in patients at intermediate cardiovascular risk.
- Published in:
- ACP Journal Club, 2016, v. 165, n. 2, p. 5, doi. 10.7326/ACPJC-2016-165-2-006
- By:
- Publication type:
- Article
Rosuvastatin reduced major cardiovascular events in patients at intermediate cardiovascular risk.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Adding candesartan-HCTZ to rosuvastatin increased adverse events but not benefits in patients at intermediate CV risk.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Combination candesartan-HCTZ did not reduce major CV events in patients at intermediate CV risk.
- Published in:
- 2016
- By:
- Publication type:
- journal article